Evicenter
P&T meetings

Tinlarebant (LBS-008)

Stargardt disease type 1

Manufacturer
Belite Bio
Regulatory submission
NDA submitted June 2026
Last updated
66 sources

Product information and disease descriptionProduct descriptionProduct informationPharmacology

Pharmacokinetics

2 evidence topics · 1 source

Pharmacokinetics and drug interactions

“healthy adults” (opens the source at this quote in a new tab)

“5 mg single dose” (opens the source at this quote in a new tab)

Pharmacokinetics and drug interactions: food

“Cmax and AUCinf ratios” (opens the source at this quote in a new tab)

“1.08–1.22” (opens the source at this quote in a new tab)